Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Corp, you should view the bigger picture and ask yourself, why is Merck so anxious to stay close as possible to combining Keytruda with Bavituximab ?
You have failed to show proof that the drug, Bavituximab ...or any PS Targeting drug ever failed vs understanding the politics in how it was stopped in phase III Sunrise trial ?
I will give you a hint, Merck with ties INTO the IDMC that stopped the Sunrise trial : )
Remember, it was not Peregrine that stopped it...it was the IDMC
Ooops, was I suppose to say that lol ....the problem is I am not on anyones payroll exept myself so I care less in how long it takes for the puzzle pieces to escape, as Shawshank redemption ...where one sits and digs and digs and DIGS
Everyone has a price though and my account could increase one morning where even I stop but it is interesting and I see why PS Targeting was sabotaged time and time again in various ways
The fines and penalties that Big Pharma and hedge funds etc pay are miniscule for the value paid back on the other end ...no ethics, but that is another problem
________
Bells Palsy patients should be infuriated if their MDs don't seek the best treatments and the increase in MDSCs and ROS etc remains a problem where PS Targeting helps.
So we have some concrete ties building and Sard Verbinnen hired to create an illusion of all illusions ...I wonder how many hedge funds have hired Sard Verbinnen in the past ?
: )
______
Bells Palsy ROS increase
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471655/#!po=1.85185
__________________
However, additional properties of these cells, including increased reactive oxygen species and inflammatory cytokine production, as well as their universal expansion in nearly all inflammatory conditions, suggest that MDSCs may be more of a normal component of the inflammatory response (â??emergency myelopoiesisâ?) than simply a pathological response to a growing tumor.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3060988/#!po=72.0779
____________________
February 9, 2015
Newly Presented Data Shows That Peregrine Pharmaceuticals' PS-Targeting Antibodies Significantly Enhance Anti-Tumor Activity of Immune Checkpoint Inhibitors PD-1 and CTLA-4 in Models of Breast Cancer and Melanoma
PS-Targeting Antibodies Block Tumor Suppression of Immune System Allowing Development of Robust Immune Responses Resulting in Statistically Significant Improvement in Anti-Tumor Activity; Specific Effects Seen in Decreased Levels of MDSCs and Other Immunosuppressive Lymphocytes and Increases in Tumor Fighting Immune Cells
TUSTIN, CA -- (Marketwired) -- 02/09/15 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced preclinical data presentations showing that the PS-targeting antibody equivalent to bavituximab combined with an anti-PD-1 antibody displayed statistically significant improvement in tumor fighting immune cells, activation signals and cytokines in a model of melanoma compared to anti-PD-1 alone. Moreover, cells that suppress the immune system from recognizing tumors, such as myeloid-derived suppressor cells (MDSCs), were reduced by more than 40% in the combination with the PS-targeting antibody versus anti-PD-1 alone. These data, further validating the immune-stimulatory mechanism of bavituximab, are outlined in an oral and poster presentation by Bruce Freimark, Ph.D., director, preclinical oncology research at Peregrine, to be made at the Keystone Tumor Immunology: Multidisciplinary Science Driving Combination Therapy meeting being held February 8-13, 2015 in Banff, Alberta, Canada. Peregrine's lead PS-targeting antibody, bavituximab, is currently being evaluated in second-line non-small cell lung cancer (NSCLC) as part of the SUNRISE pivotal Phase III clinical trial.
"These data build on our growing body of encouraging combination data and strengthen our clinical development plans as we evaluate the direction of combination therapy trials utilizing bavituximab and other checkpoint inhibitors" said Jeff T. Hutchins, Ph.D., vice president of preclinical research at Peregrine. "Our goals are to modify a tumor environment that allows more patients to respond to conventional and immune therapy. As the tumor environment switches from immuno-suppressive to immuno-stimulatory with bavituximab treatment, we believe the addition of other checkpoint inhibitors, like anti-PD-1, may increase the number of patients responding to therapy."
In the presentations titled: "Antibody-Mediated Blockade of Phosphatidylserine Enhances the Anti-Tumor Activity of Immune Checkpoint Inhibitors by Affecting Myeloid-Derived Suppressor Cells (MDSC) and Lymphocyte Populations in the Tumor Microenvironment", Dr. Freimark and his research group, along with colleagues from the University of Texas Southwestern Medical Center led by Xianming Huang, Ph.D., demonstrate that in immunocompetent preclinical models of breast cancer and melanoma, the combination of PS-targeting antibodies and anti-CTLA-4 and anti-PD1 antibodies demonstrate statistically significant anti-tumor responses than either anti-CTLA-4 or anti-PD-1 antibody alone. New data presented show statistically significant changes in levels of tumor infiltrating lymphocytes (TILs), a type of white blood cell implicated in killing tumor cells, in the PS-targeting and anti-PD-1 combination group over single treatment alone in a melanoma model. Specifically, data show increases in a number of markers used to determine immune activation, including CD3 and CD8 cells expressing PD-1, Lag-3 and CD137 (4-1BB). Furthermore, data show that CD8 T cells in the tumor had increased production of IFN-gamma and TNF-a, both known to assist in promoting immune activation and Granzyme-B which is involved in direct tumor killing.
http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=895363
Biomarkers, PS Targeting hedge funds to John Springs Stafford to Sard Verbinnen
Sometimes ....one can't control everything but ask oneself this, those that spend time on a company that likely is positioning itself for paradigm shifts across Big Pharma as we now know it....either want PS Targeting to advance or they will lose out in other ways and want it delayed as long as possible
Sard Verbinnen was brought on board for a reason
John Springs Stafford was brought on board for reasons as well
Nothing happens for no reason and Biomarkers are here for good
The following from the FDA and how quickly things change once scientifically proven Biomarkers rise up and lead the way that some in Big Pharma will not like
Interesting how the FDA has not publicly responded how inferior the FDA system has been working ...
Maybe Laura Benjamin will just say it's not her job but then again they all blame someone else. Imagine that...paid pawns when they take an oath to bring the best medicines forward unless they listen to certain Big Pharmas that tell then they must attack the individual receptors and fail fiduciary duties of the shareholder
Did Peregrine or Avid ever post ALL details of the complete IP assets transfers? I don't think so
Wonder if Laura Benjamin gets to sit in on any FDA meetings regarding betabodies or other PS Targeting activities because now since she must realize how sabotaged the prior PS Targeting trials were, it is very simple to conduct biomarker readings on all patients throughout any trial. Seres knows how to adapt and work their FDA channels but will Laura Benjamin be allowed to by the puppet masters behind David Malek?
It certainly looks like Joseph Carleone could care less about shareholders at this time and too busy talking with Louis Gerstner friends
______
Seres Therapeutics has unveiled the design of a phase 2 trial it thinks could secure FDA approval for its once-failed treatment for recurrent Clostridium difficile infection. The microbiome pioneer emerged from talks with FDA saying the regulator agrees the study may qualify as a pivotal trial if it achieves a â??persuasive clinical effect.
Cambridge, Massachusetts-based Seres went into talks with FDA earlier this year armed with its analyses of what went wrong in the earlier phase 2 which missed its primary endpoint leaving a lasting dent in the companyâ??s share priceâ??and its proposals for designing a better follow-up study. At the time, Seres asserted the trial failed because it misdiagnosed the C. difficile infection status of patients entering and during the study and gave subjects a suboptimal dose of SER-109.
Now, Seres says FDA agrees with its analyses and plans to avoid the same pitfalls in the next study.
https://www.fiercebiotech.com/biotech/embargoed-until-7am-et-after-fda-talks-seres-unveils-potentially-pivotal-trial-for-once
Trivia question regarding PS Targeting and how it is all leading to major Avid Bioservices contracts and more.....
What is the closest number of proteins related to ones immune system, that differ from a normal healthy person 18-40 ...vs 40-60 vs 60+ ? All vs the same individual groups for one with early EARLY stages of cancer before stage 1 vs stage 2 vs stage 3 vs stage 4 (does it change between types of cancer IN early stages vs late stages hmmm)
I guess before one answers one must know a good estimate for how many proteins are related to ones immune system so let's start there
100 proteins
250 proteins
500 proteins
1000 proteins
1500 proteins
2000 proteins
5000+ proteins
Now we realize how important biomarkers are and the list of proteins that do change require PS Targeting to realize which ones to pay attention to and which ones to monitor only
I never knew Merck had so many ties into so many things
____________
David Wallach
David Wallach did his M.Sc. and doctoral studies at the Department of Biological Chemistry, The Hebrew University of Jerusalem, Israel, and his postdoctoral training at the National Cancer Institute, Bethesda, Maryland, USA. He is currently a professor at the Weizmann Institute of Science, Rehovot, Israel.
His studies were the first to provide conclusive evidence that the â??type Iâ?? (anti-viral) and â??type IIâ?? (immune) interferons act through distinct mechanisms and have distinct patterns of effects.
Over the past 30 years, Prof. Wallach and his colleagues have been engaged in elucidating the mode of action of cytokines of the TNF family. They contributed to the isolating TNF, to the isolating and cloning the soluble and cells surface forms of the two TNF receptors and to the study of the shedding mechanisms of these receptors. His research group was of the first to decipher the extrinsic apoptotic cell-death pathway, to clone its major components (FADD/MORT1, caspase-8/MACH, and cFLIP/CASH) and to define their structural motifs (death domain, death-effector domain). They were also of the first to clone several of the signaling proteins that mediate effects of the TNF family on the NF-?B transcription factors. They continuously explore further the mechanisms of action of these signaling proteins and their physiological functions.
http://www.tnf2015.org/content/david-wallach
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=110833328
________
Functions of receptors of the TNF family are central to the pathology of various diseases. Since its inception, our research has been conducted with the support and collaboration of the Merck-Serono company and its Israeli subsidiary Interpharm, and has been aimed not only at acquiring basic knowledge, but also at applying this knowledge to the treatment of diseases to which members of the TNF family contribute. Part of the insights gained through this collaboration has already been applied to the treatment of chronic inflammatory diseases such as psoraisis, rheumotoid arthritis and Crohn's disease. By elucidating the intricacies of the signaling mechanisms activated by the TNF family we hope to form the basis for future development of drugs for other diseases to which this receptor family contributes.
https://www.weizmann.ac.il/Biomolecular_Sciences/Wallach/home
True, it has been no where fast for now, and Kobi Cohen can change that so let's see if he has the backings that some think they have. Who knows, maybe Teva will get a bit upset about someone else picking up the next 5%+ holdings before them
There has never been this much excitement surrounding CDMOs and that excitement is eclipsed by those that require PS Targeting / AI / biomarkers / medical devices of the future / agriculture etc
In her findings, Saris noted that the three scientists simultaneous focus on blocking the pathway to treat cancer in early 2000 shows that they were all working toward a shared goal. The court also found that conception of the inventions in the Honjo patents was the result of the collaboration of all three scientists.
https://www.dana-farber.org/newsroom/news-releases/2019/u-s--district-court-rules-dana-farber-scientist-is-an-inventor--on-six-critical-immunotherapy-patents/
-----
The Enlightenment Age of Disease ...is here and what impact will this ruling have on those that collaborated with PS Targeting to discover new biomarkers and as for upstream flipped PS being the first domino to fall, all downstream dominos may become inconsequential
Merck paying big bucks for HIF-1a 2a etc downstream Targeting that results in increased MDSCs ...when upstream ...we have flipped PS which would occur first with an anti-PS drug, then takes care of all downstreamers
_________
Targeting HIF-2α as therapy for advanced cancers.
Abstract
Hypoxia-inducible factors (HIF-1α, -2α -3α, and -β) are key factors that control hypoxia-induced carcinogenic pathways. HIF-1α is predominantly involved in the early stages of cancer, whereas HIF-2α is actively involved in the later stages; in addition, chronic (prolonged) rather than acute (short) hypoxia is a feature of metastasis and chemoresistance that occur during the later stages of cancer.
https://www.ncbi.nlm.nih.gov/m/pubmed/29753878/
______
May 21 2019
Merck has struck a deal to buy Peloton Therapeutics for $1.1 billion upfront days before the biotech was due to list on Nasdaq. The deal will give Merck control of an experimental oral HIF-2α inhibitor that could challenge Keytruda for the metastatic renal cell carcinoma (mRCC) market.
Peloton was due to go public this week and raise $150 million or more to bankroll a late-phase trial of HIF-2α inhibitor PT2977 in mRCC patients previously treated with at least one checkpoint inhibitor, such as Merckâ??s Keytruda. But a late offer from Merck has persuaded the biotech to switch lanes, taking a buyout that represents a premium on the IPO terms even before milestones are factored in.
All told, Merck could pay $1.2 billion in milestones on top of the $1.1 billion cash upfront. In return, Merck will gain a drug that is due to move into phase 3 later this year on the strength of data from 55 mRCC patients who had received at least one prior line of therapy.
https://www.fiercebiotech.com/biotech/merck-boosts-late-phase-cancer-pipeline-1-1b-peloton-buy
_________
Tumor cells adapt to the hypoxic microenvironment through the hypoxia-inducible factor (HIF) family of transcription factors. HIFs are heterodimeric proteins composed of an oxygen-sensitive alpha subunit (HIF-1α, HIF-2α, HIF-3α) and a beta subunit (HIF-β/ARNT). Both HIF-1α and HIF-2α are regulated by oxygen-dependent von Hippel-Lindau (VHL)-mediated degradation [6]. HIF-1α and HIF-2α share overlapping target genes and each one also regulates a set of unique targets. These hypoxia-dependent HIF-1α- and HIF-2α-induced genes play important roles in regulating different aspects of tumor biology such as angiogenesis, cell survival, chemo- and radio-resistance, proliferation, tumor cell plasticity, invasion and metastasis, pH regulation and metabolism, resistance to the immune system, and maintenance of cancer stem cells [6,8].
https://www.sciencedirect.com/science/article/pii/S0304383519303167
For those that accept what transpired then I guess they may trust in John Springs Stafford.
For those that don't accept what transpired, starting with Ronin Capital John Springs Stafford down playing the IP transfer and never major thoughts out of the current BOD ...then Houston, we have major problems.
Hey they may surprise me and say we had to do it this way for x, y and z reasons which are now known ...
I highly doubt it and the next thing should puzzle any shareholder...knowing we do get those milestones royalties etc etc and exosomes dealings that never fully surfaced etc etc
Maybe Dana Farber / Gordon J Freeman shouldn't have pushed to become co patent owner neither and should had accept blindly what happened?
CDMOs ...one can place a value there
Exosomes and Biomarkers and medical devices of the future ...priceless
So one either wants just a CDMO and sell out cheap or push and battle for patent rights and don't settle just for breadcrumbs
Exosomes liquid biopsy ...will ALL be looking for flipped PS on exosomes
I wonder who wanted the exosomes back to UTSWM and under what terms that were never fully disclosed
____
Together, the Peregrine and Avid Bioservices teams have the existing infrastructure, staff and expertise to develop, optimize and validate a functional assay capable of detecting PS-positive exosomes from a blood sample. Given the company's extensive experience in developing assays of this type, Peregrine does not anticipate the need to add personnel or any specialized equipment for this project. The company intends to establish clinical proof-of-concept for the test and expects to initiate partnering discussions for the program in 2017.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=123909780
Yes Biocept as they required the assistance of MD Anderson for some patents of those CTCs
I wonder who Peregrine was collaborating with at that time
_____
ABSTRACT
Background: There has been increasing interest in the detection of tumor exosomes in blood for cancer diagnostics. Most studies have focused on miRNA and protein signatures that are surrogate markers for specific tumor types. Because tumor cells and tumor-derived exosomes display phosphatidylserine (PS) in their outer membrane leaflet, we developed a highly sensitive ELISA-based system that detects picogram amounts of exosomal phospholipid in plasma as a cancer biomarker.
Methods: This report describes the development of a highly specific and sensitive ELISA for the capture of PS-expressing tumor exosomes in the blood of tumor-bearing mice. To monitor the relationship between tumor burden & tumor exosome plasma concentrations, plasma from one transplantable breast cancer model (MDA-MB-231) and 3 genetic mouse models (MMTV-PyMT; breast and KIC and KPC; pancreatic) were screened for captured exosomal phospholipid.
Results: We show that quantitative assessment of PS-expressing tumor exosomes detected very early-stage malignancies before clinical evidence of disease in all 4 model systems. tumor exosome levels showed significant increases by day 7 after tumor implantation in the MDA-MB-231 model while palpable tumors appeared only after day 27. For the MMTV-PyMT and KIC models, tumor exosome levels increased significantly by day 49 (P<=0.0002) and day 21 (P<=0.001) while tumors developed only after days 60 & 40, respectively. For the KPC model, a significant increase in blood exosome levels was detected by day 70 (P=0.023) when only preinvasive lesions are microscopically detectable.
Conclusions: These data indicate that blood PS exosome levels is a specific indicator of cancer and suggest that blood PS is a biomarker for early-stage malignancies.
...Glimpse of beg. of 7pg. article:
....
....
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=132443000
Trivia question for Avid Bioservices BOD shareholders
Who does Laura Benjamin with Oncologie and Karen Briner with Novartis like to collaborate with more and give proper credit to the research by the late Dr Phil Thorpe?
Yanping Xu with Johnson Johnson may have the answer but he will likely not be saying much....looks like sooner or later we all get to see how valuable PS Targeting has always been
______
Yanping Xu
Head of Chemistry at The Janssen Pharmaceutical Companies of Johnson & Johnson
Indianapolis, Indiana Area
Pharmaceuticals500+
Experience
Head of Chemistry
The Janssen Pharmaceutical Companies of Johnson & Johnson
May 2018 – Present 1 year 2 months
Shanghai City, China
Research Advisor
Eli Lilly and Company
May 1998 – March 2018 19 years 11 months
How does Michael Chisamore with Merck get involved with Biothera and Oncologie Laura Benjamin now fully tied into Biothera.... all the puzzle pieces will surface and PS Targeting is at the heart and center of it all. Ex Eli Lilly employees that were let go early retirement we're targeted and this gets bigger and all the puzzle pieces place John Springs Stafford in the mix to lie to shareholders and current Avid Bioservices BOD are silenced for now
How big is PS Targeting? Big enough for some to risk paying fines
____
The agreement is between Lilly and Merck, through a subsidiary. Additional details of the collaboration were not disclosed.
“Cancer is not one disease but rather more than 200 diseases, all of which have different causes and treatments,” said Richard Gaynor, M.D., senior vice president, product development and medical affairs, Lilly Oncology. “Therefore research into combinations of immune-based therapies with other agents that could address these different tumor types is important. This collaboration between Lilly and Merck represents each company’s strong commitment to patients fighting these devastating diseases.”
https://www.mrknewsroom.com/news-release/oncology-newsroom/lilly-merck-enter-collaboration-agreement-research-immuno-oncology-co
_______
Jeremy Graff ex Eli Lilly working with Laura Benjamin and they all require PS Targeting rights and knowledge
_________
https://www.biothera.com/biothera-pharmaceuticals-announces-management-changes/
Since joining Biothera Pharmaceuticals in 2014 as Chief Scientific Officer, Dr. Graff has led research demonstrating the synergy between Imprime PGG and immune checkpoint inhibitors—the focus of the Company’s clinical development plan. Under Dr. Graff’s leadership, Biothera has refined its understanding of the anti-cancer therapeutic activity of Imprime PGG and further validated its biomarker-driven, patient selection strategies. Before joining Biothera, Dr. Graff held numerous leadership positions at Eli Lilly and Company, culminating in his role in developing the Lilly Translational Oncology effort.
Thanks CJ and Cliff Hoyt and Lisa Stepp had some very interesting meetings about the future of PS Targeting ...just as the late Dr Phil Thorpe had after discovering liquid biopsies and flipped PS exosomes being required by medical devices for all sorts of fueling activities
_____
Cliff Hoyt to Akoya to Argonaut to conflicts of interest with our very own BODs
____
How many BOD members of Avid have not been upfront with Avid Bioservices shareholders and have competing interests elsewhere?
The facts are all going to surface ...slowly ...and maybe our new sit in of a CEO is too busy talking with Argonaut and no mind to PS Targeting FULL ADVANCEMENT ... with Oncologie that has some interesting partners that have direct ties back to more interesting parties
The value has always been PS Targeting IP and the CDMO contracts are only a payoff
Cliff Hoyt at Perkin Elmer when working with Lisa Stepp and Peregrine ...how many were silenced like Dr Wolchok and Martin Edelman ...and the list is quite compelling
For now, we see the beginning of ties from Cliff Hoyt to Akoya to Argonaut ...and we have a BOD tie to Argonaut
Hedge Funds and others are required for all this plan to work and the SEC to FBI to DOJ have quite a bit of info ...since John Springs Stafford playing a puppet and we get no real news from current BOD that suggested by their non actions that PS Targeting was not worthy
I guess Ronin would be ok with paying fines verse telling the truth now
_______
Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer
Facts
PS externalization during apoptosis and cell stress are mediated by scramblases Xkr8 and TMEM16, respectively.
Exposed PS is an evolutionarily conserved anti-inflammatory and immunosuppressive signal.
An astonishing number of pathogens causing major infectious diseases utilize PS and apoptotic mimicry to evade host immune responses.
PS signaling is highly dysregulated in the tumor microenvironment and autoimmune diseases.
PS-targeting therapeutics (e.g., AnxA5, bavituximab) can stimulate immune activity.
Acknowledgements
We thank Lisa Stepp and Joseph Shan for helpful discussions and critically reading the manuscript. We apologize to those whose work was not included owing to space and reference limitations. This work was supported by: Rutgers New Jersey Medical School; NIH-CA-165077 and New Jersey Health Foundation grants to RBB, DFG grants SFB 643 and SFB 1181 to MH, and to the University of Texas; Simmons Comprehensive Cancer Center, Cancer Prevention and Research Institute of Texas RP110441 and RP120670, and Peregrine Pharmaceuticals, Inc.
Author information
Author notes
R B Birge, S Boeltz, S Kumar, J Carlson, J Wanderley, D Calianese, M Barcinski, R A Brekken, X Huang, J T Hutchins, B Freimark, C Empig, J Mercer, A J Schroit, G Schett & M Herrmann
These authors contributed equally to this work.
Affiliations
Department of Microbiology, Biochemistry and Molecular Genetics, Cancer Center, Rutgers New Jersey Medical School, 205 South Orange Ave, Newark, NJ 07103, USA
R B Birge, S Kumar & D Calianese
Department of Internal Medicine 3â??Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), University Hospital Erlangen, 91054 Erlangen, Germany
S Boeltz, G Schett & M Herrmann
Peregrine Pharmaceuticals, 14282 Franklin Avenue, Tustin, CA 92780, USA
J Carlson, J T Hutchins, B Freimark & C Empig
Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
J Wanderley
Laboratório de Biologia Celular, Instituto Oswaldo Cruz, Rio de Janeiro, Brazil
M Barcinski
Division of Surgical Oncology, Department of Surgery, Hamon Center for Therapeutic Oncology Research, Dallas, TX 75390-8593, USA
R A Brekken & X Huang
Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX 75390-8593, USA
R A Brekken & X Huang
Medical Research Council Laboratory for Molecular Cell Biology, University College London, Gower Street, London WC1E 6BT, UK
J Mercer
Simmons Cancer Center and the Department of Immunology, University of Texas Southwestern Medical Center, Dallas, TX 75390 USA
A J Schroit
Full link below:
https://rdcu.be/bFBr4
_____________
Akoya Biosciences was founded in 2015 to commercialize the CODEX System to enable ultra-high multiplexing for biomarker discovery. The fundamental CODEX technology was developed in the lab of Dr. Garry Nolan at Stanford University, who has served as a pioneer in technological and computational methods to enable a better understanding of tissue architecture and its contribution to disease pathology.
The Phenopticsâ?¢ technology was originally conceived and developed by Cambridge Research & Instrumentation, co-founded by Peter Miller and Cliff Hoyt, acquired by Caliper in 2010, which was subsequently acquired by PerkinElmer in 2011. The Phenopticsâ?¢ technology was promptly adopted as the industry standard for multiplexed tissue analysis for translational and clinical research.
The partnership between PerkinElmer and Telegraph Hill Partners, announced in November of 2018, created the current Akoya Biosciences. This combined portfolio of complementary technologies will continue to fuel groundbreaking advancements in cancer immunology, immunotherapy and a wide range of pathology research.
https://www.akoyabio.com/company/about-company-history
___________
Akoya Biosciences together with our strategic partners are leading the emerging field of tissue biomarker analysis.
Ultra-high multiplexing biomarker analysis and discovery
High-throughput workflows for true quantitative pathology
Revealing basic cell-to-cell biology in intact tissues
Stratification and drug mechanism of action in clinical trials
PerkinElmer
PerkinElmer, Inc. is a global leader focused on innovating for a healthier world. The Company reported revenue of approximately $2.3 billion in 2017, has about 11,000 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index.
Argonaut Manufacturing Services, Inc.
Argonaut provides contract manufacturing in the life science and biotech arena for clients looking to leverage their supply chain. With experience supporting product launch, scale-up and revitalization, Argonaut houses over 7,500 sq.ft. of clean room production area and 3,000 sq. ft. of â??research use onlyâ? manufacturing space at their headquarters in Carlsbad, CA. Argonaut is backed by the venture capital team, Telegraph Hill Partners.
BioLegend
BioLegend develops and manufactures world-class, cutting-edge antibodies and reagents at an outstanding value to customers for biomedical research. The broad product portfolio includes flow cytometry, cell biology, and functional reagents for research in immunology, cancer research, stem cells, and more. The aggressive product development program is accomplished through technology licensing, collaborations, and internal research. BioLegend offers a wide range of custom services, including assay development, sample testing, and conjugation. BioLegend headquarters in San Diego, CA operates under an ISO 13485:2003 certified quality management system.
Indica Labs Inc.
Indica Labs software solutions provide fast, quantitative evaluation of whole slide tissues using HALO and HALO AI for image analysis and HALO Link to manage images, data, and facilitate collaboration. With unmatched ease-of-use and scalability, pharmaceutical, healthcare, and research organizations worldwide are using HALO for high-throughput, whole-slide image quantification in areas such as oncology, immuno-oncology, neuroscience, ophthalmology, metabolism, respiratory and toxicological pathology.
Keyence
Keyence is a leading supplier of sensors, measuring systems, laser markers, microscopes, and machine vision systems worldwide, Keyence is at the forefront of factory automation. Keyence strives to develop innovative and reliable products to meet the needs of our customers in every manufacturing industry. Keyence has steadily grown since 1974 to become an innovative leader in the development and manufacturing of industrial automation and inspection equipment worldwide. Our products consist of code readers, laser markers, machine vision systems, measuring systems, microscopes, sensors, and static eliminators. Today, Keyence serves over 250,000 customers in 100 countries around the world, where our name stands for innovation and excellence. Keyence Corporation of America is located in Itasca, IL.
VIB
VIB, a life sciences research institute based in Flanders, Belgium, performs basic research with a strong focus on translating scientific results into pharmaceutical, agricultural and industrial applications.
Visiopharm
Visiopharm is a world leader in Augmented Pathologyâ?¢ solutions. Leading biopharmaceutical companies, contract research organizations (CROs), academic medical centers, and hospital diagnostic pathology labs all over the world utilize the Oncotopix platform for tissue-based research and diagnostics. Oncotopix provides scientists and pathologists with a scalable software solution that fits the needs and volumes of both research and diagnostic labs. Over the past 16 years Visiopharm has grown into an international business with over 800 installations and countless more users. Visiopharm software is featured in over 1,350 scientific publications since 2010 and is compatible with leading slide scanning systems and data management software. A growing network of authorized distributors and integration partners support the growth of Visiopharm solutions on several continents including North America, Europe, and Asia. Our headquarters is in the Medicon Valley of Denmark, with a branch office in the United Kingdom and a North American office in Broomfield, Colorado.
Ximedica, Inc.
Ximedica is ISO 13485:2012 Certified and FDA Registered. As a full-service development firm, Ximedica has an exclusive focus on medical products and over 25 years of experience developing medical devices, combination products and consumer healthcare products.
https://www.akoyabio.com/company/our-partners
__________
Now all it takes is a slight of hand connection from Ronin - John Springs Stafford to a Sumitomo affiliation etc and this little heist of an IP transfer comes to a screeching halt ...no worries, Stafford or Ronin is used to settling with SEC with no admission of guilt and will gladly pay a fine
_____
Current Assignee: Biothera Inc
DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
....the invention may also be carried out with complement activating immune suppression-relieving agents. One example may be bavituximab.
https://patents.google.com/patent/US10111901
___
April 13, 2017 published
April 19, 2017 assigned to Ronin...I mean Biothera!
July 10, 2035 and that is a long time
Inventor Nandita BoseKeith GORDENAnissa S H. ChanSteven LEONARDOJeremy GRAFFXiaohong QiuTakashi KANGASKathryn A. FRASERAdria BYKOWSKI JONASNadine OTTOSONRoss Fulton Current Assignee Biothera Inc
Worldwide applications
2015 CN WO JP EP 2016 US 2018 US
Application US15/386,887 events
2014-07-10
Priority to US201462022754P
2014-11-06
Priority to US201462076094P
2015-02-13
Priority to US201562115895P
2015-04-20
Priority to US201562149892P
2015-07-10
Priority to PCT/US2015/039977
2016-12-21
Priority to US15/386,887
2016-12-21
Application filed by Biothera Inc
2017-04-13
Publication of US20170100425A1
2017-04-19
Assigned to BIOTHERA, INC.
2018-10-30
Application granted
2018-10-30
Publication of US10111901B2
2019-06-03
Application status is Active
2035-07-10
Anticipated expiration
https://patents.google.com/patent/US10111901
I wouldn't really call it out for nothing as any Sumitomo ties of a company could easily spend some cash and as Cramer told us ...it can be "fun"
I wonder if Brian Weston at Ronin Capital with John Springs Stafford could give the go ahead on algo change and make this more interesting
Interesting ties that Sumitomo has...actually, Peregrine collaborator or Avid/Oncologie collaborator Biothera with CMO Dr Jose Iglesias just so happens to be with Boston Biomedical and the puzzle pieces are alive and kicking
Why is John Springs Stafford so quiet? He used to enjoy sending out shareholder letters
Dr Iglesias needs better glasses to see the 3D live images of a drugs MOA to see what happens first....unless he has a personal conflict, and RPG can use an MD that remains quiet
Maybe one of these days they surprise us
_________
Welcome Dr. José Iglesias to ResearchPoint Global as Medical Director, Oncology.
We are pleased to announce that Dr. José Iglesias has joined ResearchPoint Global, a WuXi AppTec company as Medical Director, Oncology. Dr. Iglesias will serve as the expert in all new oncology programs and assist in the development of a proactive oncology strategy that will open doors and attract sponsors seeking a CRO with extensive oncology expertise.
“We are very fortunate to have attracted José as our own internal oncology expert,” says Alfonso Alanis, RPG’s Chief Medical Officer. “I have known José for over twenty years, and he is a very gifted scientist. José is well known and well respected in the field of clinical oncology globally and has a broad network which includes some of the principal thought leaders in modern oncology. He has worked with some of the most traditional oncology platforms as well as the most novel ones including immuno-oncology and genomics.”
Throughout his 28-year career in the pharmaceutical industry, Dr. Iglesias exhibited his scientific expertise while occupying global senior leadership positions at Apobiologix, Biothera, Bionomics, Celgene, Abraxis BioScience, Amgen Canada, and Eli Lilly. Dr. Iglesias has designed and led all phases of oncology clinical trials, as well as authored or co-authored more than 60 publications in the field of oncology. In his most recent role as Vice President of Medical and Clinical Affairs, he furthered the development of oncology biosimilars at Apobiologix.
“I am delighted to join the dynamic RPG team,” says Dr. Iglesias. “I look forward to helping PRG build up a solid oncology strategy and assisting it in becoming a preferred partner in oncology clinical development. RPG’s approach is unique in the CRO industry and has great potential to be very successful in furthering the progress of oncology clinical research worldwide.”
Dr. Iglesias will attend the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL from June 1 to June 5. He would be pleased to liaise and network with investigators, organizations, and institutions interested in moving forward their Oncology clinical development projects. To set an appointment with Dr. Iglesias, please contact him at jiglesias@researchpoint.com, or at his mobile phone, +1 (416) 618-1729.
https://www.researchpointglobal.com/rpg-welcomes-jose-iglesias-oncology/
_____
Let's go Dr Iglesias ....what activates what? : )
Developer of a cancer immunotherapy platform technology intended to improve immune health. The company's cancer immunotherapy platform technology works as an immunological ignition switch to activate a host of anti-tumor immune system responses that enhance the therapeutic efficacy of immune checkpoint inhibitors and other monoclonal antibodies, enabling cancer patients to begin treatment quickly, resulting in a higher likelihood of a successful treatment.
https://pitchbook.com/profiles/company/84208-69
Targeting flipped PS is that activation that THEN allows the rogue protein pathways to get those protein pathways moving
Will Oncologie prove out to be just a middle man and squeeze profits away from the longer term PS Targeting shareholders?
John Springs Stafford and Ronin look like they will be ok paying bigger fines and all to delay and slow play PS Targeting
More and more MOA of Big Pharma Drugs are going to realize that flipped PS is targeted first ...and MOAs of other drugs may have to be overturned
Laura E Benjamin all over Biothera and who on our BOD likes Sensient ? I guess we may now debate how Independent Joseph Carleone truly is...
https://www.sensientflavorsandfragrances.com/images/uploads/pdf/BiotheraPartner.pdf
_____
Joseph Carleone biography
Dr. Joseph Carleone, Ph.D. is Independent Director of the Company. Dr. Carleone is Chairman of the Board of AMPAC Fine Chemicals LLC (since December 2015), a leading manufacturer of pharmaceutical active ingredients. Prior to this position, Dr. Carleone was President and Chief Executive Officer of American Pacific Corporation (2010 to 2015), a leading custom manufacturer of fine and specialty chemicals and propulsion products. While at American Pacific Corporation, he also served as President and Chief Operating Officer (2006 to 2009), as a director (2006 to 2015), and as Chairman of the Board (March 2013 to February 2014, when it was acquired by H.I.G. Capital, LLC). Dr. Carleone has also served or currently serves as an officer and/or a director of several directly or indirectly wholly-owned subsidiaries of American Pacific Corporation. Since November 27, 2017, Dr. Carleone has served as a director of Avid Bioservices, Inc. (formerly known as Peregrine Pharmaceuticals, Inc.) (NASDAQ: PPHM). After his election as a director, he was named non-executive Chairman of Avid Bioservices’ Board of Directors. Avid Bioservices is a clinical stage biopharmaceutical company focused on developing therapeutics to stimulate the body’s immune system to fight cancer. Dr. Carleone received his bachelor’s degree in Mechanical Engineering from Drexel University, Philadelphia, Pennsylvania, in 1968; his masters’ degree in Applied Mechanics from Drexel University in 1970; and his doctorate degree in Applied Mechanics from Drexel University in 1972.
https://www.google.com/amp/s/wallmine.com/people/42102/joseph-carleone.amp
David Carbone was a key KOL that knew the value of PS Targeting IP and gave some very helpful information to Biothera regarding Bavituximab and the anti-PS platform
I wonder what the late Paul Carbone would say about his son that stays quiet like Dr Jedd Wolchok and the others ....what oath is taken when one becomes an MD? I though it was something about bringing the best treatments forward and don't sell out the patients just because some John Springs Stafford friends want to make money and delay PS Targeting
_____
It is time for the FDA to allow 3D imaging from several various technologies to support the MOA of certain drugs and let us SEE the targeting of flipped PS that occurs BEFORE other protein pathways shift back to safety and restore ones immune system to optimal levels before any other toxic drugs wants to be shoved down the FDA approval line
Everyone best wake up and realize that there was a reason why CDMO Avid is being granted big contracts
I guess it they push the price up north enough, everyone becomes Wolchok like and shuts the hell up
_______
Good news for Avid but will anyone within BOD fulfill fiduciary duty?
Is it all about milestones or royalties or FDA approvals or other CDMO contracts?
I always liked to push the envelope and always questioned anything to everything, but I guess we can all agree that not big advancements would be possible without imaging technologies. As said before Big Pharma used to be allowed legally to pay off up and coming technologies from smaller biotechs that threatened Billion dollar patented toxic drugs that were approved based upon decreasing the size of the tumor lol
Imagine that....just because toxic drugs were killing you the damn FDA approved them for years
Imaging changed that course and we KNOW Roche has been playing with PS Targeting imaging for years YEARS
_______
Imaging allows proof of Biomarkers and proof of toxicities and proof that the FDA has been approving many drugs for years on a major flaw, but that is because Big Pharma lobbyists are #1 and being #1 is not always great because as said before a picture is worth a thousand words and a thousand words tucked into a bill for legislatures to approve are worthless
Imaging from GE, ThermoFisher etc etc based upon PS Targeting ...then utilized by Google or Amazon or IBM Watson or Microsoft etc will be the key
Why did John Springs Stafford show up when he had employees that are ok with being fined for trading etc and how many other traders are connected by the hip with Ronin?
https://www.sec.gov/Archives/edgar/data/704562/000101968710001070/filename1.htm
Things should become more interesting when all involved become public, then combined with years of sabotage to limit and conceal the value behind PS Targeting ...many will look like fools for accepting new jobs or other incentives all just to delay PS Targeting
________
Roche: The ultimate insider view
Medical imaging plays an increasingly important role in the development of new drugs
And how does imaging fit into research and development at Roche? Three years ago, Roche formed an Imaging Sciences group within the TRS organization (led by Anna-Lena Nordström) in recognition that more and more pRED projects are using imaging technology to improve the understanding of disease biology and to aid in drug development.
Since that time, part of the original imaging group has been integrated into Oncology Discovery & Translational Area (DTA) and is now named Oncology Translational Imaging (OTI). Team members include Abi Keelara, Tapan Nayak, Jean Tessier and Gudrun Zahlmann. The group’s expertise helps pRED colleagues answer important questions like: Does the drug reach the tumor? Is the drug causing pharmacodynamics changes in a patient’s tumor? Is the drug causing the tumor to change shape or size? In some cases, imaging can help with decisions regarding which dose should be used.
“In the Oncology DTA, non-invasive imaging tools are used alongside with tissue-based diagnostics to gain a more complete view of disease and response to therapies. This helps to improve decision making,” explains David Geho, who heads the OTI group.
Among the imaging modalities used in pRED projects are MRI, Positron Emission Tomography (PET), and CT scans. These can be used in global, multicenter studies and have contributed to decision making across multiple oncology programs. The OTI team is also exploring the use of advanced image analysis tools to assess changes in three-dimensional (3-D) tumor volumes as a means to more sensitively detect treatment effects on tumors.
In addition to the in-house experts on the Imaging Sciences team, Roche benefits from academic alliances such as the Dutch Imaging Hub (DIH). The hub connects pRED with three world-renowned institutes for advanced imaging: Free University Medical Center in Amsterdam, University Medical Center Groningen, and Radboud University Nijmegen Medical Center. Eight Roche postdocs and PhDs are working on numerous studies in oncology as part of the DIH collaboration.
Both OTI and the experts at the DIH are keenly interested if radiolabeled therapeutic antibodies (often called “radiotracers”) can be used in drug development. PET scanning with these tracers has been incorporated into several oncology programs to assess the drug’s tumor-targeting characteristics and to show how a new drug is distributed within the patient’s body.
“We are eager to work with pRED development teams on the implementation of molecular imaging tools that will enable us to make better drug development decisions,” David says.
http://www.roche.com/media/roche_stories/roche-stories-2013-10-03.htm
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=93323563
_______________
AF will never write another story like he did in the past regarding Bavituximab. He was told to stay away by at least 30ft lol and AF will look like the Cramer follower he is once PS Targeting gets the 1st approval
Maybe the US will not be the 1st place of approval : )
Glad to see you here, a very good sign
Avid Bioservices in line to receive milestones / royalties / $$$ / from PS Targeting and cumulative IP, and remember the CTO Confidential Treatment Order that does not go public till 2021 where some details of that Oncologie IP transfer were not fully disclosed
Like ALL drugs, Mechanism of Actions can be learned, fine tuned and realized
Bavituximab is one that is unique and we are square in the middle of Biomarkers and protein pathways that are affected by where dozens of downstream actions occur all initiated by some global, upstream action ....and of course, there is nothing better than live, 3D imaging....where FDA officials can not deny that the Targeting of Flipped PS PtdSer Phosphatidylserine occurs ....and that sets off a series of events
I have been tracking many events over the years including hundreds of key thesis papers that are approved by key players in academia
There is simply no time to post the most important ones re: IO drugs etc etc but what is important is that the FDA will receive some major backlash with continued, corrupt like actions that side with some within Big Pharma
What future expansions at Avid are based upon PS Targeting IP?
I like the words "upon activation" because there are hundreds of academia type research that is approved by key researchers ...and if we compare to Bavituximab....the events that occur AFTER PS Targeting will disrupt Big Pharma as we officially have been forced, to know it.
________
Bavituximab MOA
https://www.xvivo.net/animation/bavituximab-mechanism-of-action-moa/
_____________
Kole Thomas Roybal - UTSWM Thesis
T cell activation occurs through interaction with an antigen-presenting cell (APC). Upon activation, signaling ensues with the coordination of dozens of diverse signaling molecules in space and time, a feature of cell signaling we call ‘spatiotemporal patterning’. We performed a systems-scale analysis of the spatiotemporal patterning of T cell signaling and have found that it is highly diverse. Over 50 signaling sensors were imaged in live primary T cells activated with APCs under various physiological stimulation conditions, and no two signaling intermediates showed the same dynamic localization. The activation environment controlled spatiotemporal features of T cell signaling and specific spatiotemporal features correlated with efficient T cell activation. To identify underlying cell biological mechanisms controlling spatiotemporal organization of signaling, we complimented our live cell imaging with microscopy across multiple scales and identified a dense transient F-actin network that extends from a highly interdigitated T cell:APC interface several micrometers deep into the T cell lamellum. Systems-scale imaging revealed a large network of proximal T cell signaling intermediates that localized to the lamellal actin network and shared the spatial, temporal, and mobility features of F-actin. Interference with lamellal actin dynamics modulated the activity of the associated proteins and impaired IL-2 production. These data strongly suggest that the transient deep F-actin network by controlling lamellal localization modulates the activity of a substantial part of the T cell signal transduction system. As a next step in understanding how spatiotemporal dynamics of signaling controls T cell activation, we have developed a quantitative 4D analysis approach for signaling networks and coupled it with traditional cell biological techniques to uncover higher order mechanisms of the control of actin dynamics by CD28 co-stimulation during T cell activation. A group of nine actin regulatory proteins that mediate actin polymerization, capping, and severing were assessed and CD28 co-stimulation was required for their sustained activity at the T cell:APC interface. WAVE2 and Cofilin were especially sensitive to blockade of CD28 signaling. Functional relevance of the loss of WAVE2 and Cofilin enrichment was shown by the treatment of T cells with constitutively active Rac1 and Cofilin, which bypassed the requirement of co-stimulation for normal actin dynamics and AKT activation. This study highlights how a systems analysis of actin regulation could identify mechanisms that are inaccessible to more traditional single protein/gene approaches.
https://utswmed-ir.tdl.org/handle/2152.5/1587?show=full
___________
Interesting, Bavituximab mentioned in this patent like as if, many know it is required for CAR-T therapy to avoid those Cytokine Storms / Cytokine Release syndrome ...as Dr Jedd Wolchok KNOWS
BINDING-TRIGGERED TRANSCRIPTIONAL SWITCHES AND METHODS OF USE THEREOF
Publication number: 20180355011
Abstract: The present disclosure provides binding-triggered transcriptional switch polypeptides, nucleic acids comprising nucleotide sequences encoding the binding-triggered transcriptional switch polypeptides, and host cells genetically modified with the nucleic acids. The present disclosure also provides chimeric Notch receptor polypeptides, nucleic acids comprising nucleotide sequences encoding the chimeric Notch receptor polypeptides, and host cells transduced and/or genetically modified with the nucleic acids. The present disclosure provides transgenic organisms comprising a nucleic acid encoding a binding triggered transcriptional switch polypeptide and/or a chimeric Notch receptor polypeptide of the present disclosure. Binding triggered transcriptional switch polypeptides and chimeric Notch receptor polypeptides of the present disclosure are useful in a variety of applications, which are also provided.
Type: Application
Filed: December 4, 2017
Publication date: December 13, 2018
Inventors: Wendell A. Lim, Leonardo Morsut, Kole T. Roybal
https://patents.justia.com/inventor/leonardo-morsut
https://patents.google.com/patent/US9670281B2/en
___________
I wonder how many biotech companies have sent into the FDA live 3D images at the cellular level in support of their respective drugs Mechanism of Action. Flipped PS is becoming a nightmare to witness firsthand and geez, actual imaging proves some MOAs are correct and many MANay others flawed. Let us await to see some of the pending lobbyist initiatives surrounding Biomarkers. A picture is worth a thousand words and a thousand words from a Big Pharma lobbyist is not worth much at all.
Flipped PS aka PtdSer aka Phosphatidylserine thresholds, control much of the most important protein pathway biomarkers.
Imagine that, half of the FDA approved drugs can be tossed out the window and welcomes PS Targeting
David Mott
https://www.nea.com/team/david-mott
Scott Gottlieb
https://www.nea.com/team/scott-gottlieb-md
New Enterprise Associates – which has locations in Chevy Chase, Maryland, Menlo Park, California, and others – said Wednesday that it had rehired former FDA Commissioner Scott Gottlieb as a special partner. Gottlieb had previously served as venture partner at the firm from 2007 until 2017, when he was appointed as the country’s top drug regulator. He stepped down as FDA commissioner in March, and Ned Sharpless – former director of the National Cancer Institute – currently serves in his place as acting commissioner. Following his resignation, Gottlieb also returned to another prior position, as a fellow at conservative think tank the American Enterprise Institute.
https://medcitynews.com/2019/05/scott-gottlieb-returns-to-nea-this-time-with-some-valuable-experience-under-his-belt/
Good afternoon Mr Gottlieb, we were wondering if you had any information regarding Peregrine Pharmaceuticals or the advances being made and any possible filings with the FDA?
SG: I am sorry to say that I can't comment on those matters.
Yes we assumed that would be the response, how about having your old job back and a nice signing bonus?
SG: I am still tied to the agency...the FDA...you know?
Well we have some plans that would benefit you nicely, if you decided to resign from the agency and no laws prohibiting you from waiting 30 days and move forward with our plans?
SG: Thanks for the offer but I have no reason to leave the FDA at this time.
Think about it and you can always leave as cover due to e-cigs / vaping and we can even help you in support of those addictions to teenagers etc if you can help us?
SG : Help with what?
Well we can set up a meeting with David Mott and yourself if you decide to leave the FDA... these biomarkers for Immunotherapy are a major concern.
Patients do deserve best and PS Targeting works so well, that some have been paid to spread lies it seems so ask why, some simply keep trying
Will Laura Benjamin CEO of Oncologie International dare advance PS Targeting fully, or is it too much for her to Bayer?
A company formed within 30 days of Peregrine making a last minute (no competitive bidding as Medarex shareholders went thru ) breadcrumb deal ? Those answers have yet to be seen
Avid Bioservices receives how much from royalties and milestones and bonuses from PS Targeting approvals? Plus all manufacturing
When Billions have been spent on cancer progress and we are right back to prior times when Big Pharma refused to seek answers of using ones immune system to fight back ....now they must, due to imaging and imaging that proves that PS Targeting works
From humans to animals to plants, (Upstream) PS Targeting controls the downstream events
There are Billions of lives to feed out there, Crop Science has just now caught up with The Enlightenment Age of Disease ...that will make crop producers Billions and save them Billions by not wasting toxic additives to crops that do more harm than good
Australia a good place to start and time to get to the root of the problem!
It is finally setting up nicely for that volume tomorrow. Microsoft vs Google etc ...one has to wonder where they get the data to even know what to sell to insurance companies for health analysis
Flipping PS is everywhere, from the first moment the threshold is passed on a SINGLE diseased cell
I guess they call it inflammation and increased MDSCs
Where did Paul Jerome Lytle go after Peregrine ? Did it not seem odd that we never heard much back from the investigations and maybe US Attorney Mark Daniel Lytle can help out, with some shareholder concerns ....or maybe investigations still ongoing with the John Springs Stafford agenda to stop the advancement of PS Targeting ?
Much info has been suppressed surrounding PS Targeting collaborations and looks like the CDMO road to profitability is nearing, though the real story is the IP behind PS Targeting
They mention profitability more than once. I wonder if the contracts that will bring Avid to profitability were initiated by Steve King or Roger Lias or ?? Looks like the next CEO in place will get the credit
The individuals involved in certain PS Targeting activity also have some other excuses in common
Personal reasons
Dr Jedd Wolchok backs out of talking about how PS Targeting combo helps stop off target toxicities etc due to personal reasons
Roger Lias CEO Peregrine / Avid leaves due to personal reasons
FDA Commissioner Scott Gottlieb resigns due to personal reasons (1 month later poached over to New Enterprise Associates)
There were lots more and I am sure David Mott has his finger in the mix
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134141703
Such a shame that many in Big Pharma never really wanted a cure to many such a disease it seems, and the few that resisted falling in line to Big Pharma just so happen to suddenly pass away. There seems to be an awakening going on though because it can't be hidden much longer
Yes, I still own PPHM Peregrine Pharmaceuticals or as they call it CDMO Avid Bioservices now.
So why do you think Stafford wanted to split off the IP at Peregrine?
For why John Spring Stafford sold at $40 Xencor stock .... Maybe because he wanted to buy back at $30
The question now is INmunebio ties to Xencor and John Stafford
INmunebio needs PS Targeting IP
John Springs Stafford needs help